Probe signals were amplified by incubation at 65°C for 30 min and the accumulation of dsDNA products were monitored using a Corbett
RotorGeneTM 6000 real-time PCR machine (Corbett Research, Mortlake, Australia). Probe signals were also visualised on a 1.5% agarose gel to verify the specificity of probe-template binding. click here Nucleotide sequence accession numbers The ERG11 sequences of the study isolates have been deposited in the GenBank database with the following accession numbers: FJ159508, FJ159444 to FJ159507 inclusive and FJ232378 to FJ232396 inclusive. Acknowledgements We thank Rosemary Handke for assistance with the susceptibility testing of the isolates from the Women’s and Children’s Hospital, Adelaide, OkCha Lee for help with the culture-based identification of C. albicans and Maryann Princevic for her assistance in sequencing. This study was supported by a Centre for Clinical Research Excellence Grant (grant # 264625) from the National Health and Medical Research
Council of Australia to TCS. Electronic supplementary material Additional file 1: Padlock probes and primers used for RCA. The data provide the names and sequences of the probes and primers used in the study for RCA. (DOC 78 KB) References 1. Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in this website critically ill non-immunosuppressed patients. Lancet selleckchem Infect Dis 2003, 3:685–702.CrossRefPubMed 2. Odds FC, Webster CE, Mayuranathan P, Simmons PD: Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. GPX6 J Med Vet Mycol 1988, 26:277–283.CrossRefPubMed 3. White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998, 11:382–402.PubMed 4. Morschhauser J: The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002, 1587:240–248.PubMed 5. Perea
S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF: Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001, 45:2676–2684.CrossRefPubMed 6. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995, 39:1–8.PubMed 7. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF: Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998, 42:2932–2937.PubMed 8. Kelly SL, Arnoldi A, Kelly DE: Molecular genetic analysis of azole antifungal mode of action. Biochem Soc Trans 1993, 21:1034–1038.PubMed 9.